Sequential PET/CT and pathological biomarker crosstalk predict response to PD-1 blockers alone or combined with sunitinib in propensity score-matched cohorts of cancer of unknown primary treatment

Sequential PET/CT and pathological biomarker crosstalk predict response to PD-1 blockers alone or combined with sunitinib in propensity score-matched cohorts of cancer of unknown primary treatment

IntroductionThe efficacy of immune checkpoint inhibitors (ICIs), including toripalimab and pembrolizumab, has not been confirmed in the treatment of cancer of unknown primary (CUP), which has a very poor prognosis. Combined with anti-angiogenic therapies, ICIs are hypothesized to be effective in pro...

Full description

Bibliographic Details
Main Authors: Youlong Wang, Qi Huang, Guanqing Zhong, Jun Lv, Qinzhi Guo, Yifei Ma, Xinjia Wang, Jiling Zeng
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Oncology
Subjects:
cancer of unknow primary
PET/CT (18)F-FDG
sunitinb
EFGR
VEGFR
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1191611/full

Similar Items

Similar Items